O23 Ixekizumab (IXE) vs. adalimumab (ADA) for the treatment of PSA: 52-week efficacy and safety outcomes

Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Soyi Liu Leage(Eli Lilly (United States)), Mani Haschemi Nassab(Medizinische Hochschule Hannover), Christophe Sapin(Eli Lilly (United States)), Klaus Machold(Medical University of Vienna), Burkhard Möller(Hirslanden Salem-Spital), Roberto Ranza(Hospital de Clínicas)
Lara D. Veeken
April 1, 2020
10.1093/rheumatology/keaa110.022
Cited by 2

Related Papers

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
|Annals of the Rheumatic Diseases|2006|798
Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis
|JAMA|2014|739